Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

This article is based on that report. The study paper itself was not reviewed.

The question matters because of who is using these drugs. According to the Society, about one in five women aged 50 to 64 report current or past use of a GLP-1 obesity medication. That is the highest share of any demographic group in the U.S. The report notes that weight gain at midlife is common. It says the gains are largely driven by aging, though menopause-related factors can contribute to fat accumulation and redistribution.

According to the report, the study was a retrospective observational cohort. It included nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide. All were over 45 with a body mass index above 27. The researchers concluded that hormone therapy was associated with significantly greater and sustained weight loss with semaglutide.

Tirzepatide told a different story. Women using hormone therapy lost more weight at first. By the end, the difference did not reach statistical significance, according to the report. In plain terms, the gap was too small or too uncertain to rule out chance. The report gives no figures for how much extra weight the hormone users lost.

The design limits what the result can say. A retrospective study looks back at records of what women already did. It cannot show that hormones caused the extra weight loss. Women who use hormone therapy may differ from those who do not in ways that also affect weight. That is a general caution about this kind of study, not a finding from the report.

Lead author Dr. Regina Castaneda of Mayo Clinic Florida called the signal consistent with earlier, smaller studies. She said it is biologically plausible, citing preclinical data that suggest estrogen and GLP-1 signaling may work together. She also noted the effect was stronger with semaglutide than tirzepatide, which she said deserves further study.

She was direct about the limits. According to the report, she said: "it is too early to draw firm conclusions." She added that the findings need confirmation in welldesigned prospective trials. She also said weight loss is not an indication for menopause hormone therapy.

That is the main takeaway for women on a GLP-1. This result does not support starting hormones to lose weight. Dr. Stephanie Faubion, the Society's medical director, said more research is needed. She said the study highlights the value of considering menopause-specific factors in personalized weight management.

The full results will be presented at The Menopause Society's 2026 Annual Meeting in San Diego, October 20–24. The next test is a prospective trial that compares women on a GLP-1 with and without hormone therapy.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36 Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health